Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results


1.		Study Evaluating Sirolimus in Non-Melanoma Skin Cancer in Kidney Transplant Recipients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Prevention				Closed				18 and over				Pharmaceutical / Industry				0468H1-407 NCT00129961


2.		Sirolimus-Based Immunosuppression in Liver Transplantation for High Risk Hepatocellular Carcinoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 70				Other				#4279 NCT00328770

Last Modified: 7/2/2008 First Published: 7/23/2004


3.		Phase III Randomized Study of Prednisone and Cyclosporine or Tacrolimus With Versus Without Mycophenolate Mofetil in Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				4 and over				NCI				FHCRC-1697.00 ROCHE-FHCRC-1697.00, NCT00089141, UMN-2004UC007

Last Modified: 7/11/2007


4.		Phase I/II Study of Sirolimus (Rapamycin) Combined with Methotrexate and Cyclosporine as Treatment for Graft-versus-Host Disease in Patients with Hematologic Disorders Who Are Receiving Bone Marrow Transplants from Mismatched Related Donors (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care				Closed				13 and over				NCI				FHCRC-1096.00 NCI-H96-0928, NCT00002790

Last Modified: 3/11/2008 First Published: 10/1/2002


5.		Phase I/II Study of Sirolimus in Patients With Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				UCLA-0203078 NCI-G02-2114, NCT00047073

Last Modified: 4/21/2005 First Published: 7/23/2004


6.		Phase I/II Pilot Study of Sirolimus, Tacrolimus, and Methotrexate for the Prevention of Acute Graft-Versus-Host Disease in Patients With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care				Closed				Per primary treatment protocol				NCI				FHCRC-1811.00 NCT00089037

Last Modified: 11/1/2006 First Published: 2/20/2004


7.		Phase II Study of Sirolimus as Secondary Treatment for Patients With Chronic Graft-Versus-Host Disease Who Had An Inadequate Response to Prior Systemic Treatment

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Closed				Any age				NCI				FHCRC-1706.00 NCT00079183


8.		Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Closed				18 to 65				Other				05-154 NCT00133367


9.		Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				60 and over				Other				0402008 GOELAMS, PHRC, NCT00235560

Last Modified: 6/5/2007 First Published: 4/20/2006


10.		Phase II Study of Myeloablative Conditioning Regimen Comprising Total-Body Irradiation and Metabolism-Based Cyclophosphamide in Patients Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Cancer and Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 70				NCI				FHCRC-1998.00 NCT00317785

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute